HIV/AIDS: Current Treatment (ART), Viral Suppression & Life Expectancy
HIV is manageable with antiretroviral therapy (ART). No cure yet, but viral suppression allows near-normal lifespan.
ART Principles
- Combination ≥3 drugs from ≥2 classes – prevents resistance.
- Goal: Plasma HIV RNA <50 copies/mL (undetectable) within 3–6 months.
- U=U: Undetectable = Untransmittable (sexual transmission).
Preferred Initial Regimens (DHHS / WHO)
- Integrase inhibitor (INSTI) + 2 NRTIs:
- Bictegravir/TAF/FTC (Biktarvy) – single tablet, once daily, few interactions.
- Dolutegravir + TAF/FTC or TDF/FTC.
- Raltegravir + TAF/FTC (twice daily).
- Avoid NNRTI-based (efavirenz) due to side effects/resistance.
Monitoring
- Viral load q3–4 mo (suppressed) → q6 mo.
- CD4 count q3–6 mo (if >500, optional).
- Renal, hepatic, lipid, glucose, bone density (TAF better than TDF).
Complications of Untreated/Unsuppressed HIV
- AIDS-defining illnesses (opportunistic infections, malignancies).
- Chronic inflammation → cardiovascular, renal, hepatic, neurocognitive, bone disease.
Prevention
- PrEP (TDF/FTC or TAF/FTC) – >99% effective for sexual transmission.
- PEP (72 hr post-exposure).
- TasP (Treatment as Prevention) – U=U.
With early ART, life expectancy approaches general population. Adherence is lifelong.
HIV & AIDS - Related Articles
- HIV and Eye Health: Understanding Potential Complications
- HIV in Heterosexual Populations: Women Disproportionately Affected
- Analgesics & NSAIDs: Understanding Pain Relief & Inflammation
- Comprehensive Guide to HIV Testing: Types, Methods & What to Expect
- Understanding HIV Symptoms: Early Signs & What to Do
- HIV Transmission: Why Environmental Surfaces Are Not a Risk
- HIV Transmission: Which Body Fluids Carry the Virus?
